

# CRONOS

A U S T R A L I A


## ADAYA MEDICINAL CANNABIS PRODUCTS SALES UPDATE – AVERAGE 200%+ QoQ GROWTH

**Melbourne, Australia, 20 May 2021** – Cronos Australia Limited (ASX:CAU, “Cronos Australia” or the “Company”) is pleased to provide a sales update on its proprietary range of Adaya-branded medicinal cannabis products.

Adaya products are specifically

- Manufactured to Australian and EU GMP standards.
- Australian manufactured, with future packaging to bear the “Australian Made” kangaroo seal.
- Value-priced, underpinning patient accessibility and affordability.
- Widely available through distributors and pharmacies nationwide to ensure no stock outs, which would negatively impact patients.

The Adaya range was launched on 1 July 2020 and has resonated positively with both patients and healthcare professionals, resulting in an average quarter-on-quarter increase in sales revenue of more than 200%, with forecast sales in Q4 FY21 expected to approach \$600,000.



The current Adaya range is comprised of the following five products:

- Adaya 1:25 - CBD dominant Medicinal Cannabis Oil
- Adaya CBD 100 - CBD only Medicinal Cannabis Oil
- Adaya 10:10 - THC: CBD Balanced Medicinal Cannabis Oil
- Adaya 20:1 - THC dominant Medicinal Cannabis Oil
- Adaya THC 26 - THC only Medicinal Cannabis Oil

“The solid quarter-on-quarter growth in sales of our Adaya range of products is validation of our strategy to ensure Australian patients can access Australian manufactured, Australian and EU GMP compliant, affordable and available medicinal cannabis products. In the development of these products, we have listened to patients and healthcare professionals about their needs and we believe this has driven this significant increase in demand,” said Rodney Cocks, CEO of Cronos Australia.

**\*\* ENDS \*\***

## **About Cronos Australia**

Cronos Australia Limited is listed on the ASX (ASX:CAU). The vision of Cronos Australia is to become a leading health and wellness company in the Asia Pacific region through the creation and distribution of premium medical and consumer cannabinoid products and services. The Company's largest shareholder is Cronos Group Inc. (NASDAQ:CRON; TSX:CRON).

- Cronos Australia distributes the Adaya and PEACE NATURALS™ ranges of medicinal cannabis products nationwide in Australia through medical practitioners via the Special Access Scheme and Authorised Prescribers. See [www.adaya.co](http://www.adaya.co)
- Cronos Australia owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes face-to-face and nationwide telehealth consultations with patients seeking access to medicinal cannabis. See [www.cannadoc.com.au](http://www.cannadoc.com.au) and [www.cannadoc.co.nz](http://www.cannadoc.co.nz)
- Cronos Australia has established operations in Hong Kong and Japan for the development of ranges of cannabinoid brands and products and their distribution into global consumer markets. The first two ranges of products are Bathing Shed, see [www.bathingshed.com](http://www.bathingshed.com), and FCTR, see [www.getfctr.com](http://www.getfctr.com)
- Cronos Australia has a 50/50 joint venture with A&S Branding, the founders of Sukin Organic Skincare, for the development of CBD products for sale in domestic and export markets.

## **Authorised by**

Rodney Cocks, Chief Executive Officer and Executive Director

## **Contact**

### **Cronos Australia Limited**

Rodney Cocks

Chief Executive Officer & Executive Director

1300 799 491

[info@cronosaustralia.com](mailto:info@cronosaustralia.com)

## **Forward-looking statements**

This announcement may include forward-looking statements. These forward-looking statements are based on Cronos Australia's expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Cronos Australia, which could cause actual results to differ materially from such statements. Cronos Australia makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.